肺癌诊断市场－全球产业规模、份额、趋势、机会和预测，按类型、检测方法、地区和竞争格局划分，2020-2030年预测

2024年全球肺癌诊断市场规模为15.4亿美元，预计2030年将以6.99%的复合年增长率成长至23.1亿美元。全球肺癌诊断市场涵盖了用于肺癌早期检测和精准分型的各种技术和流程。市场成长的主要驱动因素是全球肺癌发生率的不断攀升以及人们对早期筛检益处的认识不断提高。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球肺癌诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（小细胞肺癌、非小细胞肺癌）
  • 依检测方法（影像检查、切片、痰细胞学检查、分子检测、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美肺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲肺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区肺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲肺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲肺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球肺癌诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Sanofi SA
• Roche Diagnostics Corporation
• BioMerieux SA
• Qiagen NV
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Illumina Inc.
• Johnson & Johnson
• Abbott Laboratories Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Lung Cancer Diagnostics Market, valued at USD 1.54 Billion in 2024, is projected to experience a CAGR of 6.99% to reach USD 2.31 Billion by 2030. The Global Lung Cancer Diagnostics Market encompasses a diverse range of technologies and procedures utilized for the early detection and precise characterization of lung cancer. Market growth is primarily driven by the escalating global incidence of lung cancer and heightened awareness surrounding the benefits of early screening.

Key Market Drivers

The increasing global incidence of lung cancer represents a fundamental driver for the diagnostics market. This rising number of new cases directly necessitates expanded diagnostic capabilities for early detection and precise staging, which are vital for effective treatment planning and improved patient outcomes. The escalating incidence creates continuous demand on healthcare systems for accessible diagnostic tools, encompassing advanced imaging modalities and comprehensive molecular profiling. According to the American Cancer Society and the International Agency for Research on Cancer, in April 2024, "Global Cancer Statistics, 2024" reported an estimated 2.5 million cases of lung cancer were newly diagnosed worldwide in 2022.

Key Market Challenges

The substantial capital investment required for advanced diagnostic technologies poses a notable challenge to the expansion of the Global Lung Cancer Diagnostics Market. The high acquisition, installation, and ongoing maintenance costs associated with state-of-the-art imaging equipment, advanced molecular profiling platforms, and specialized laboratory infrastructure significantly limit their widespread accessibility and adoption. This financial barrier is particularly impactful in emerging economies, where healthcare budgets are often constrained and robust medical infrastructure is less developed.

Key Market Trends

The expansion of global lung cancer screening programs represents a significant trend driving the diagnostics market by systematically increasing the early detection of the disease. These initiatives, increasingly backed by updated guidelines, broaden the eligible population for low-dose computed tomography (LDCT) screening, leading to a greater demand for imaging equipment, skilled radiologists, and subsequent diagnostic procedures. For instance, according to the American Cancer Society, in June 2024, a study found that the up-to-date lung cancer screening prevalence in the United States was 18.1% in 2022, highlighting ongoing efforts to improve screening rates. This programmatic expansion ensures that more individuals at high risk are undergoing regular examinations, facilitating earlier diagnosis and intervention.

Key Market Players

• Sanofi S.A.
• Roche Diagnostics Corporation
• BioMerieux SA
• Qiagen N.V.
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Illumina Inc.
• Johnson & Johnson
• Abbott Laboratories Inc.

Report Scope:

In this report, the Global Lung Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Diagnostics Market, By Type:

• Small Cell Lung Cancer
• Non-small Cell Lung Cancer

Lung Cancer Diagnostics Market, By Test:

• Imaging Test
• Biopsy
• Sputum Cytology
• Molecular Test
• Others

Lung Cancer Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lung Cancer Diagnostics Market.

Available Customizations:

Global Lung Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Small Cell Lung Cancer, Non-small Cell Lung Cancer)
  • 5.2.2. By Test (Imaging Test, Biopsy, Sputum Cytology, Molecular Test, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Lung Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Test
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lung Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Test
  • 6.3.2. Canada Lung Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Test
  • 6.3.3. Mexico Lung Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Test

7. Europe Lung Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Test
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lung Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Test
  • 7.3.2. France Lung Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Test
  • 7.3.3. United Kingdom Lung Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Test
  • 7.3.4. Italy Lung Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Test
  • 7.3.5. Spain Lung Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Test

8. Asia Pacific Lung Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Test
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lung Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Test
  • 8.3.2. India Lung Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Test
  • 8.3.3. Japan Lung Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Test
  • 8.3.4. South Korea Lung Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Test
  • 8.3.5. Australia Lung Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Test

9. Middle East & Africa Lung Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Test
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lung Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Test
  • 9.3.2. UAE Lung Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Test
  • 9.3.3. South Africa Lung Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Test

10. South America Lung Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Test
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lung Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Test
  • 10.3.2. Colombia Lung Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Test
  • 10.3.3. Argentina Lung Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Test

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lung Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sanofi S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Roche Diagnostics Corporation
• 15.3. BioMerieux SA
• 15.4. Qiagen N.V.
• 15.5. Agilent Technologies, Inc.
• 15.6. Thermo Fisher Scientific Inc.
• 15.7. AstraZeneca plc
• 15.8. Illumina Inc.
• 15.9. Johnson & Johnson
• 15.10. Abbott Laboratories Inc.

16. Strategic Recommendations

17. About Us & Disclaimer